Executive Committee
The Board of Directors has delegated the management of the company to the CEO, who, in turn, has delegated certain powers to the members of the Executive Committee. The Organizational Regulations of the Board of Directors govern, among others, the delegation from the Board of Directors to the CEO and the sub delegation by the CEO. The regulations can be viewed at medmix.swiss/en/Investors/Governance (under Downloads).
Members of the Executive Committee
René Willi, Chief Executive Officer and member of the Executive Committee, is a Swiss citizen born in 1967.
Binding interests: None
Before joining medmix as CEO on June 1, 2024, René Willi was the Chief Executive Officer of the Global Oral Reconstruction Group at Henry Schein Inc. and a member of the Henry Schein Inc. Executive Management Committee, a company he joined in in 2013. René Willi was previously Executive Vice President, Surgical Business Unit, at Institut Straumann AG in Basel, Switzerland, which he joined in 2005. Prior to Straumann, René held roles in the cardiovascular division of Medtronic. Before that, he served as a management consultant with McKinsey & Company. René started his career in plant engineering as a process engineer (Ems-Inventa) and senior manager sales & engineering (Von Roll Inova AG). René Willi was a member of medmix’ Board of Directors from 2022 until he joined the company as CEO.
René holds a Master’s degree in Chemical Engineering, a PhD in Technical Sciences and a postgraduate Master’s degree in Industrial Engineering and Management from the Swiss Federal Institute of Technology ETH Zurich. He is an alumnus of the Medtronic marketing leader program of the Wharton School, University of Pennsylvania.
Jennifer Dean, Chief Financial Officer and member of the Executive Committee, is an Australian citizen born in 1968.
Binding interests: Member of the Board of the Australian-Swiss Chamber of Commerce since 2022. Member of the Board of Directors at Medartis AG since 2024.
Jennifer Dean has been the CFO of medmix since September 2021. Prior to the incorporation and separate listing of medmix Ltd, Jennifer Dean acted as the Chief Financial Officer for the Applicator Systems division of Sulzer Ltd (from 2017). She was CFO for Product Lines at GE Power Services from 2015 to 2017. Prior to this, she held a number of positions at Alstom, including Vice President Finance for the Thermal Services division (2013 to 2015), Finance Director for the Gas Turbine Product Line (2010 to 2013), and Finance Director for Environmental Control Systems & Carbon Capture Systems (2006 to 2010).
Jennifer Dean holds a Bachelor’s degree in Economics from Macquarie University, Sydney, Australia, and is a chartered accountant (Chartered Accountants Australia & New Zealand) and associate member of the Governance Institute of Australia.
Itee Satpathy, Chief HR and Sustainability Officer and member of the Executive Committee, is a Swiss citizen born in 1978.
Binding interests: None.
Before joining medmix Ltd in December 2021, Itee Satpathy was appointed Global Head of People Development and Internal Communications at Sulzer in 2018. Prior to joining Sulzer, she led Talent Development and Diversity at Syngenta (2013 to 2017). Previously, she held various roles of increasing responsibility at Novartis across the Human Resources function, including leadership and organization development, talent management, and diversity and inclusion (2003 to 2012). Itee started her career in India with ICICI Bank before moving to Switzerland in 2003.
Itee Satpathy holds a Master’s degree (Diploma) in Human Resources Management from XLRI School of Management, Jamshedpur, India.
Xavier Schops, Chief Legal Officer, Company Secretary, Head of Corporate Affairs and member of the Executive Committee, is a French citizen born in 1968.
Binding interests: Member of the Board and Treasurer of ACC Europe – Association of Corporate Counsel.
Xavier Schops has headed the Legal and Compliance department and served as Company Secretary since August 2022. He joined the Executive Committee on November 1, 2023, since then he has also served as Head of Corporate Affairs. He joined medmix from Sonova AG (2019–2022), where he served as General Counsel, then supported Mergers & Acquisitions. Previously, he was General Counsel for Europe, Middle East and Africa at PPG Industries (2009–2016) and Vice President & Chief Counsel Europe for Mondelez International (2016–2019). Xavier Schops started his career at the Michelin Group, for which he worked in Europe and Asia.
Xavier Schops holds a post-graduate degree in Corporate Law and Tax from Paris University (Pantheon-Assas) and a Master’s degree in Corporate Finance and Accounting from the Neoma Business School.
Girts Cimermans stepped down as Chief Executive Officer on April 10, 2024. Details of former members of the Executive Committee are provided in the corporate governance sections of the full-year reports for financial year 2023 and previous financial years, available at medmix.swiss/investors/financial-reports (under Downloads).
Number of permitted activities
No member of the Executive Committee may hold more than five mandates, of which no more than one may be in listed companies (see Art. 33 of the Articles of Association at medmix.swiss/en/Investors/Governance; under Downloads). Exceptions (e.g., for mandates held at the request of medmix) are also defined in Art. 33 of the Articles of Association. All members of the Executive Committee comply with these requirements and no exceptions were granted in the reporting period.
Management contracts
There are no management contracts existing with third parties. None of the Executive Committee members has a contract with a notice period exceeding 12 months.